apomorphine has been researched along with Impotence in 142 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 4 (2.82) | 18.7374 |
1990's | 8 (5.63) | 18.2507 |
2000's | 110 (77.46) | 29.6817 |
2010's | 18 (12.68) | 24.3611 |
2020's | 2 (1.41) | 2.80 |
Authors | Studies |
---|---|
Bhatia, P; Brioni, JD; Chang, R; Cowart, M; Daanen, JF; Donnelly-Roberts, DL; Hollingsworth, PR; Hsieh, GC; Kolasa, T; Latshaw, SP; Lynch, JJ; Martino, BR; Miller, LN; Moreland, RB; Nakane, M; Namovic, MT; Nelson, SL; Patel, M; Rohde, J; Stewart, AO; Sullivan, JP; Terranova, MA; Uchic, ME | 1 |
Bhatia, P; Brioni, JD; Chang, R; Donnelly-Roberts, DL; El Kouhen, O; Hakeem, AA; Henry, R; Hollingsworth, PR; Hsieh, GC; Kolasa, T; Marsh, KC; Martino, B; Matulenko, MA; Miller, LN; Moreland, RB; Mortell, K; Nakane, M; Namovic, MT; Patel, MV; Stewart, AO; Terranova, MA; Uchic, ME; Wetter, JM | 1 |
Brioni, JD; Chang, R; Cowart, MD; Darbyshire, JF; Donnelly-Roberts, DL; El-Kouhen, OF; Gintant, G; Hakeem, AA; Hollingsworth, PR; Hsieh, GC; Kolasa, T; Marsh, KC; Martin, R; Martino, BR; Matulenko, MA; Miller, LN; Moreland, RB; Mortell, K; Nakane, M; Namovic, MT; Nelson, SL; Patel, MV; Rohde, JJ; Stewart, AO; Sullivan, JP; Terranova, MA; Uchic, ME; Wetter, JM | 1 |
Chen, G; Dong, J; Feng, N; Hu, L; Wu, Y; Yu, D | 1 |
Crestani, S; da Silva-Santos, JE; Leitolis, A; Linder, ÁE | 1 |
Ballesteros, J; Guillén, V; Lopez-Argumedo, M; Rueda, JR; Solà, I | 1 |
Chen, G; Chen, J; Chen, Y; Dai, Y; Jiang, H; Yang, B; Yu, W; Zang, F; Zhu, L | 1 |
Chen, G; Chen, J; Chen, Y; Dai, Y; Yang, B; Yu, W | 1 |
Albersen, M; Campbell, J; Milenkovic, U; Roussel, E | 1 |
Wang, BQ | 1 |
Elhenawee, M; Hashem, H; Ibrahim, AE | 1 |
Fan, Q; Jin, BF; Li, TF; Liu, T; Sun, ZX; Zhou, YC | 1 |
Chen, M; Liu, L; Qin, WB; Qiu, HB; Wang, BX; Wang, JT; Xu, H | 1 |
Hou, SC; Liu, W; Luan, X; Qi, HY; Sun, LJ; Wang, WM; Weng, BW; Xu, L; Zhu, H | 1 |
Alkan, E; Balbay, MD; Basar, MM; Halici, Z; Karakus, E; Ugan, RA; Un, H | 1 |
Afif-Abdo, J; Cortado, P; Damião, R; Faria, G; Glina, S; Koff, W; Pompeo, AC; Sabaneeff, J; Teloken, C; Torres, LO; Wroclawski, E; Yamasaki, R | 1 |
Colpi, GM; Cormio, L; Giammusso, B; Guastella, B; Ludovico, G; Montorsi, F; Panzironi, C; Ponchietti, R; Soli, M | 1 |
Nyírády, P; Riesz, P; Rusz, A | 1 |
Mulhall, JP | 4 |
Main, M; Morgan, F; Riley, A | 1 |
Cheng, B; Hu, W; Li, S; Liu, T; Tian, Y | 1 |
Adams, MA; Adams, SM; Blaser, MC; Hannan, JL; Oldfield, L; Pang, JJ; Pang, SC | 1 |
Albersen, M; Lue, TF; Mwamukonda, KB; Shindel, AW | 1 |
Kumar, R; Nehra, A | 1 |
Albersen, M; Lue, TF; Orabi, H | 1 |
Ribarič, S | 1 |
Bretsztajn, L; Eardley, I; Mohee, A | 1 |
Thomas, JA | 1 |
Ichise, J; Yokokawa, K | 1 |
Kumon, H; Nagai, A | 1 |
Lyngdorf, P | 1 |
Anastasiadis, AG; Shabsigh, R | 1 |
Cestari, A; Deho', F; Guazzoni, G; Montorsi, F; Rigatti, P; Salonia, A; Stief, C | 1 |
Hauri, D; Müntener, M; Praz, V; Suter, S | 1 |
Anchisi, D; De Vito, ML; Deho, F; Fazio, F; Heaton, J; Montorsi, F; Perani, D; Rigatti, P; Rigiroli, P; Salonia, A; Scifo, P | 1 |
Berding, G; Bergh, S; Hagemann, JH; Jonas, U; Knapp, WH; Sleep, DJ; Stief, CG | 1 |
Gallé, G; Trummer, H | 1 |
Tan, RS | 1 |
Buller, KM; Crane, JW; Day, TA; Spencer, SJ | 1 |
Montorsi, F | 1 |
Amornvejsukit, T; Choeypunt, N; Kongkanand, A; Opanuraks, J; Tantiwong, A; Tantiwongse, K | 1 |
Costa, P | 1 |
Hedon, F | 1 |
Erdei, E; Papp, G | 1 |
Steers, WD | 1 |
Anchisi, D; Fazio, F; Heaton, JP; Montorsi, F; Perani, D; Rigatti, P; Rigiroli, P; Salonia, A; Scifo, P; Zanoni, M | 1 |
Gaines, KK | 1 |
Schultheiss, D; Stief, CG | 1 |
Agnello, C; Caruso, S; DiMari, L; Farina, M; Giammusso, B; Intelisano, G | 1 |
Martínez, R; Pomerol, JM; Puigvert, A; Rodríguez-Villalba, R | 1 |
Curt, A; Hauri, D; Reitz, A; Schurch, B; Strebel, RT; Tenti, G | 1 |
Bertol, E; Fineschi, V; Karch, SB; Mari, F; Riezzo, I | 1 |
Athanasopoulos, A; Barbalias, G; Chrysanthopoulou, A; Giannitsas, K; Gyftopoulos, K; Markou, SA; Perimenis, P; Tsota, I | 1 |
Hellstrom, WJ; Kendirci, M | 1 |
Briganti, A; Gallina, A; Montorsi, F; Rigatti, P; Salonia, A; Suardi, N | 1 |
Jackson, G | 1 |
Eardley, I; Edwards, A; Hole, J; MacDonagh, R; Wright, P | 1 |
Athanasopoulos, A; Barbalias, G; Giannitsas, K; Gyftopoulos, K; Liatsikos, E; Markou, S; Perimenis, P | 1 |
Engelmann, U; Sommer, F | 1 |
Basu, A; Ryder, RE | 1 |
Almasio, PL; Anello, G; Curto, F; Pavone, C; Pavone-Macaluso, M; Serretta, V | 1 |
Fontana, F; Frea, B; Gontero, P; Montorsi, F; Zitella, A | 1 |
Kloner, RA; Reffelmann, T | 1 |
Hatzichristou, DG; Hatzimouratidis, K | 1 |
Hu, LQ; Hu, WL | 1 |
Dinsmore, WW | 1 |
Hellstrom, WJ; Kendirci, M; Walls, MM | 1 |
Adaikan, G; Becher, E; Brock, G; Carrier, S; Carson, C; Christ, G; Corbin, J; DeBusk, R; Eardley, I; Francis, S; Hedlund, H; Hutter, A; Jackson, G; Kloner, R; Lin, CS; Lin, S; McCullough, A; McVary, K; Nehra, A; Padma-Nathan, H; Porst, H; Schulman, C; Seftel, A; Sharlip, I; Stief, C; Teloken, C | 1 |
Xu, G; Xu, Y | 1 |
Barbieri, L; Briganti, A; Chun, FK; Dehò, F; Karakiewicz, PI; Montorsi, F; Rigatti, P; Salonia, A; Zanni, G | 1 |
Dachille, G; Ludovico, GM; Pagliarulo, A; Pagliarulo, V; Ralph, D | 1 |
Landtblom, AM | 1 |
Boshier, A; Maclennan, KM; Shakir, SA; Wilton, LV | 1 |
Gopalakrishanan, G; Tharyan, P | 1 |
Behre, HM; Burkart, M; Jungwirth, A; Porst, H | 1 |
Görlich, HD; Potempa, DM; Potempal, AJ; Stolpmann, RM | 1 |
Tan, DQ; Yao, Y; Zhang, J | 1 |
Miner, MM; Seftel, AD | 1 |
Fu, Q; Lv, JJ; Zhang, H | 1 |
Carson, CC | 1 |
Cheng, Y; Li, YG; Wei, AY | 1 |
Kiely, ME; Lal, S; Thavundayil, JX | 1 |
Adams, MA; el-Rashidy, R; Heaton, JP; Johnston, B; Morales, A | 1 |
Giuliano, F | 1 |
Hughes, AJ; O'Sullivan, JD | 1 |
Moncada Iribarren, I; Sáenz de Tejada, I | 1 |
Trummer, H | 1 |
Gottlieb, S | 1 |
Baba, K; Carrier, S; Iwamoto, T; Lue, TF; Morgan, DM; Nunes, L; Yajima, M | 1 |
Cowley, G | 1 |
Buttler, S; Dula, E; Edmonds, A; Keating, W; O'neil, J; Siami, PF | 1 |
Heaton, JP | 3 |
Roumeguère, T | 1 |
Segraves, RT | 1 |
Cohan, P; Korenman, SG | 1 |
Andersson, KE | 1 |
Giuliano, F; Padma-Nathan, H | 1 |
Bukofzer, S; Dula, E; George, M; Perdok, R | 1 |
Porst, H | 1 |
Wagner, G | 1 |
Morales, A | 1 |
Bukofzer, S; Livesey, N | 1 |
Cutler, D | 1 |
Bukofzer, S; Edmonds, AL; George, M; Mulhall, JP | 1 |
Aversa, A; Fabbri, A | 1 |
Hatzichristou, DG; Pescatori, ES | 1 |
Argiolas, A; Hedlund, H | 1 |
Mirone, VG; Stief, CG | 1 |
Rampin, O | 1 |
Buvat, J; Montorsi, F | 1 |
Altwein, JE; Heaton, JP | 1 |
Buttler, S; Edmonds, A; Fagan, TC; Marbury, T; Taylor, A | 1 |
Altwein, JE; Keuler, FU | 1 |
Allard, J; Giuliano, F | 2 |
Anastasiadis, AG; Burchardt, M; Ghafar, MA; Shabsigh, R | 1 |
Bukofzer, S; Hibberd, M; Mallard, N; Ströberg, P; Von Keitz, AT | 1 |
Carrier, S; Simmerman, N; Vachon, P; Zahran, AR | 1 |
Castaneda, J; Castell, R; Hurley, D; Lammers, PI; Lipezker, M; Loehr, LA; Lowrey, F; Ponce de Leon, R; Rubio-Aurioles, E | 1 |
Dean, J; Heaton, JP; Sleep, DJ | 1 |
Köhn, FM | 1 |
O'Sullivan, JD | 1 |
Adams, MA; Brien, SE; Gofton, WT; Heaton, JP; Smallegange, C | 1 |
Lenk, S | 1 |
Benassi-Benelli, A; Ferrari, F | 1 |
Ackman, CF; Assalian, P; Kiely, ME; Lal, S; Stewart, JD; Thavundayil, JX | 1 |
Bari, M; Segraves, K; Segraves, RT; Spirnak, P | 1 |
Dubrovsky, B; Grassino, A; Kiely, ME; Lal, S; Nair, NP; Tesfaye, Y; Thavundayil, JX; Thompson, TR | 1 |
Alexandre, L; Benoit, G; Bensadoun, H; Jardin, A; Puech, A | 1 |
Ackman, D; Blundell, P; Gardiner, RJ; Lal, S; Laryea, E; Nair, NP; Negrete, J; Thavundayil, JX | 1 |
60 review(s) available for apomorphine and Impotence
Article | Year |
---|---|
Apomorphine for the Treatment of Erectile Dysfunction: Systematic Review and Meta-Analysis.
Topics: Administration, Sublingual; Adult; Aged; Apomorphine; Erectile Dysfunction; Humans; Male; Middle Aged; Treatment Outcome; Young Adult | 2020 |
An update on emerging drugs for the treatment of erectile dysfunction.
Topics: Animals; Apomorphine; Dopamine Agonists; Erectile Dysfunction; Humans; Male; Phosphodiesterase 5 Inhibitors; Vasodilator Agents | 2018 |
Future directions in erectile dysfunction therapy.
Topics: Adrenergic alpha-Antagonists; Apomorphine; Clinical Trials as Topic; Dopamine Agonists; Erectile Dysfunction; Humans; Male; Phentolamine; Phosphodiesterase Inhibitors | 2000 |
Evaluation and treatment of erectile dysfunction.
Topics: Apomorphine; Equipment and Supplies; Erectile Dysfunction; Humans; Male; Phosphodiesterase 5 Inhibitors; Primary Health Care; Referral and Consultation; Urogenital Surgical Procedures | 2011 |
Central nervous system agents and erectile dysfunction.
Topics: alpha-MSH; Amino Acids; Apomorphine; Central Nervous System Agents; Dopamine Agonists; Erectile Dysfunction; Humans; Male; Melanocortins; Nitric Oxide; Penile Erection; Peptides, Cyclic; Phosphodiesterase 5 Inhibitors; Selective Serotonin Reuptake Inhibitors | 2011 |
The pharmacological properties and therapeutic use of apomorphine.
Topics: Alzheimer Disease; Animals; Apomorphine; Dogs; Dopamine Agonists; Erectile Dysfunction; Female; Humans; Male; Parkinson Disease; Receptors, Adrenergic, alpha; Receptors, Dopamine; Receptors, Serotonin; Substance-Related Disorders | 2012 |
The evaluation of apomorphine for the treatment of erectile dysfunction.
Topics: Administration, Sublingual; Animals; Apomorphine; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Evaluation; Drug Evaluation, Preclinical; Erectile Dysfunction; Humans; Male; Randomized Controlled Trials as Topic; Treatment Failure; United States | 2012 |
Pharmacological aspects of erectile dysfunction.
Topics: Adult; Aged; Alprostadil; Apomorphine; Drug Interactions; Erectile Dysfunction; Humans; Male; Middle Aged; Papaverine; Penile Erection; Phentolamine; Piperazines; Purines; Sildenafil Citrate; Sulfones; Testosterone; Trazodone | 2002 |
[Preclinical studies of apomorphine hydrochloride].
Topics: Animals; Apomorphine; Biogenic Monoamines; Brain; Dopamine; Dopamine Agonists; Erectile Dysfunction; Humans; Male; Oxytocin; Penile Erection; Penis; Rats | 2002 |
[Clinical evaluation of apomorphine HCl].
Topics: Apomorphine; Clinical Trials as Topic; Dopamine Agonists; Erectile Dysfunction; Humans; Male; Randomized Controlled Trials as Topic | 2002 |
Erectile dysfunction.
Topics: 3',5'-Cyclic-GMP Phosphodiesterases; Alprostadil; Apomorphine; Brain; Cyclic Nucleotide Phosphodiesterases, Type 5; Erectile Dysfunction; Humans; Male; Penile Prosthesis; Penis; Phosphodiesterase Inhibitors; Phosphoric Diester Hydrolases; Piperazines; Purines; Sildenafil Citrate; Sulfones | 2003 |
Pharmacological management of erectile dysfunction.
Topics: Administration, Oral; Adrenergic alpha-Antagonists; Alprostadil; Apomorphine; Carbolines; Drug Combinations; Erectile Dysfunction; Humans; Imidazoles; Injections; Male; Papaverine; Phentolamine; Phosphodiesterase Inhibitors; Piperazines; Purines; Sildenafil Citrate; Sulfones; Tadalafil; Triazines; Vardenafil Dihydrochloride; Vasodilator Agents | 2003 |
[Erectile dysfunction: reasonable diagnostics and treatment in general practice].
Topics: Administration, Oral; Adrenergic alpha-Antagonists; Adult; Age Factors; Aged; Algorithms; Alprostadil; Apomorphine; Cohort Studies; Contraindications; Dopamine Agonists; Erectile Dysfunction; Family Practice; Female; Humans; Male; Meta-Analysis as Topic; Middle Aged; Piperazines; Purines; Risk Factors; Sexual Partners; Sildenafil Citrate; Sulfones; Vasodilator Agents; Yohimbine | 2003 |
The etiology of erectile dysfunction and mechanisms by which drugs improve erection.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Apomorphine; Erectile Dysfunction; Humans; Male; Penile Erection; Phentolamine; Smoking | 2003 |
Novel treatment options for overlapping yet distinct erectile dysfunction and andropause syndromes.
Topics: Androgens; Apomorphine; Dopamine Agonists; Erectile Dysfunction; Humans; Male; Phosphodiesterase Inhibitors; Piperazines; Purines; Sildenafil Citrate; Sulfones; Testosterone | 2003 |
Tolerability and safety of apomorphine SL (Ixense (TM) ).
Topics: Apomorphine; Dopamine Agonists; Erectile Dysfunction; Humans; Male | 2003 |
Multidimensional nature of apomorphine SL (Ixense) therapy.
Topics: Apomorphine; Dopamine Agonists; Erectile Dysfunction; Humans; Male; Penis | 2003 |
Anxiety and erectile dysfunction: a global approach to ED enhances results and quality of life.
Topics: Anxiety; Apomorphine; Dopamine Agonists; Erectile Dysfunction; Humans; Male; Psychotherapy; Quality of Life | 2003 |
[Conservative treatment of erectile dysfunction].
Topics: Administration, Oral; Adrenergic alpha-Antagonists; Alprostadil; Apomorphine; Dopamine Agonists; Erectile Dysfunction; Humans; Imidazoles; Impotence, Vasculogenic; Injections; Male; Nitric Oxide; Papaverine; Phosphodiesterase Inhibitors; Piperazines; Psychotherapy; Purines; Sildenafil Citrate; Sulfones; Triazines; Vacuum; Vardenafil Dihydrochloride; Vasodilator Agents | 2003 |
Viability and safety of combination drug therapies for erectile dysfunction.
Topics: Alprostadil; Apomorphine; Dopamine Agonists; Drug Therapy, Combination; Erectile Dysfunction; Humans; Male; Phosphodiesterase Inhibitors; Piperazines; Purines; Sildenafil Citrate; Sulfones; Vasodilator Agents | 2003 |
Oral drug treatment of erectile dysfunction.
Topics: 3',5'-Cyclic-GMP Phosphodiesterases; Apomorphine; Carbolines; Cyclic Nucleotide Phosphodiesterases, Type 5; Erectile Dysfunction; Humans; Imidazoles; Male; Phosphodiesterase Inhibitors; Phosphoric Diester Hydrolases; Piperazines; Purines; Sildenafil Citrate; Sulfones; Tadalafil; Triazines; Vardenafil Dihydrochloride | 2003 |
Intranasal apomorphine. Nastech Pharmaceutical.
Topics: Administration, Intranasal; Animals; Apomorphine; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Contraindications; Dopamine Agonists; Erectile Dysfunction; Female; Humans; Male; Sexual Dysfunctions, Psychological; Structure-Activity Relationship | 2004 |
Emerging oral drugs for erectile dysfunction.
Topics: Administration, Oral; Administration, Sublingual; Adult; Aged; Apomorphine; Carbolines; Comorbidity; Cross-Over Studies; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Dopamine Agonists; Double-Blind Method; Drug Interactions; Erectile Dysfunction; Humans; Imidazoles; Male; Middle Aged; Multicenter Studies as Topic; Nitric Oxide; Phosphodiesterase Inhibitors; Piperazines; Purines; Randomized Controlled Trials as Topic; Second Messenger Systems; Sildenafil Citrate; Sulfones; Tadalafil; Triazines; Vardenafil Dihydrochloride; Vasodilator Agents | 2004 |
Sexual dysfunction and diabetes.
Topics: Alprostadil; Apomorphine; Diabetes Complications; Diabetes Mellitus; Erectile Dysfunction; Humans; Life Style; Male; Medical History Taking; Penile Prosthesis; Phosphodiesterase Inhibitors; Risk Factors; Self Administration; Testosterone; Vacuum | 2004 |
Future options for combination therapy in the management of erectile dysfunction in older men.
Topics: 3',5'-Cyclic-GMP Phosphodiesterases; Adrenergic alpha-Antagonists; Aged; Alprostadil; Animals; Apomorphine; Clinical Trials as Topic; Cyclic Nucleotide Phosphodiesterases, Type 5; Dopamine Agonists; Drug Therapy, Combination; Erectile Dysfunction; Humans; Male; Phosphodiesterase Inhibitors; Phosphoric Diester Hydrolases; Testosterone | 2004 |
New oral drugs for erectile dysfunction.
Topics: Apomorphine; Carbolines; Dopamine Agonists; Erectile Dysfunction; Humans; Imidazoles; Male; Phosphodiesterase Inhibitors; Piperazines; Randomized Controlled Trials as Topic; Sulfones; Tadalafil; Triazines; Vardenafil Dihydrochloride | 2004 |
New treatment options for erectile dysfunction in patients with diabetes mellitus.
Topics: Adult; Aged; Apomorphine; Diabetes Complications; Erectile Dysfunction; Half-Life; Humans; Male; Middle Aged; Penile Erection; Phosphodiesterase Inhibitors; Piperazines; Prevalence; Purines; Quality of Life; Randomized Controlled Trials as Topic; Sildenafil Citrate; Sulfones | 2004 |
Pharmacotherapy of erectile dysfunction: focus on cardiovascular safety.
Topics: Administration, Oral; Apomorphine; Blood Pressure; Cardiovascular Diseases; Contraindications; Dopamine Agonists; Drug Interactions; Erectile Dysfunction; Humans; Hypotension; Male; Nitric Oxide Donors; Patient Selection; Phosphodiesterase Inhibitors; Piperazines; Purines; Risk Assessment; Sildenafil Citrate; Sulfones | 2005 |
A comparative review of the options for treatment of erectile dysfunction: which treatment for which patient?
Topics: Administration, Oral; Alprostadil; Apomorphine; Carbolines; Constriction; Contraindications; Dopamine Agonists; Drug Combinations; Enzyme Inhibitors; Erectile Dysfunction; Humans; Imidazoles; Male; Papaverine; Patient Satisfaction; Penile Prosthesis; Penis; Phentolamine; Phosphodiesterase Inhibitors; Piperazines; Purines; Regional Blood Flow; Sildenafil Citrate; Sulfones; Tadalafil; Treatment Failure; Triazines; Vardenafil Dihydrochloride; Vasodilator Agents | 2005 |
[Pharmacotherapy for erectile dysfunction].
Topics: Animals; Apomorphine; Erectile Dysfunction; Humans; Male; Phosphodiesterase Inhibitors; Piperazines; Purines; Rats; Sildenafil Citrate; Sulfones; Yohimbine | 2005 |
Available and future treatments for erectile dysfunction.
Topics: Apomorphine; Erectile Dysfunction; Humans; Male; Phentolamine; Phosphodiesterase Inhibitors; Testosterone; Yohimbine | 2005 |
Central nervous system agents in the treatment of erectile dysfunction.
Topics: Apomorphine; Central Nervous System Agents; Clinical Trials as Topic; Dopamine Agonists; Erectile Dysfunction; Humans; Male | 2005 |
A comparative review of apomorphine formulations for erectile dysfunction : recommendations for use in the elderly.
Topics: Aged; Apomorphine; Dosage Forms; Dose-Response Relationship, Drug; Drug Administration Routes; Erectile Dysfunction; Humans; Male | 2006 |
Treatment of erectile dysfunction in multiple sclerosis.
Topics: Alprostadil; Apomorphine; Dopamine Agents; Erectile Dysfunction; Humans; Male; Multiple Sclerosis; Phosphodiesterase Inhibitors; Psychotherapy; Vasodilator Agents | 2006 |
Erectile dysfunction.
Topics: Adult; Alprostadil; Apomorphine; Carbolines; Erectile Dysfunction; Humans; Imidazoles; Male; Penile Erection; Penile Prosthesis; Piperazines; Purines; Sex Counseling; Sildenafil Citrate; Sulfones; Tadalafil; Triazines; Vardenafil Dihydrochloride; Yohimbine | 2006 |
[Apomorphine and erectile dysfunction].
Topics: Apomorphine; Dopamine Agonists; Erectile Dysfunction; Humans; Male; Penile Erection | 2007 |
Centrally acting mechanisms for the treatment of male sexual dysfunction.
Topics: alpha-MSH; Animals; Apomorphine; Autonomic Nervous System; Dopamine; Dopamine Agonists; Erectile Dysfunction; Growth Hormone-Releasing Hormone; Humans; Male; Melanocortins; Muscle, Smooth; Nitric Oxide; Norepinephrine; Opioid Peptides; Penile Erection; Peptides, Cyclic; Phosphodiesterase Inhibitors; Serotonin; Treatment Outcome | 2007 |
[Treatment per os of disorders of erection].
Topics: Administration, Oral; Adrenergic alpha-Antagonists; Antidepressive Agents, Second-Generation; Apomorphine; Cyclic GMP; Dopamine Agonists; Enzyme Inhibitors; Erectile Dysfunction; Humans; Male; Phentolamine; Piperazines; Purines; Sildenafil Citrate; Sulfones; Trazodone; Yohimbine | 1997 |
Pharmacological treatment of erectile dysfunction.
Topics: Adrenergic alpha-Antagonists; Alprostadil; Apomorphine; Dopamine Agonists; Erectile Dysfunction; Humans; Male; Muscle Relaxation; Papaverine; Phentolamine; Phosphodiesterase Inhibitors; Piperazines; Purines; Sildenafil Citrate; Sulfones; Vasodilator Agents | 1999 |
[Oral therapy of erectile dysfunction].
Topics: Administration, Oral; Adrenergic alpha-Antagonists; Adult; Apomorphine; Dopamine Agonists; Erectile Dysfunction; Humans; Male; Phentolamine; Phosphodiesterase Inhibitors; Piperazines; Purines; Selective Serotonin Reuptake Inhibitors; Sildenafil Citrate; Sulfones; Trazodone; Yohimbine | 2000 |
Apomorphine: an update of clinical trial results.
Topics: Adolescent; Adult; Aged; Apomorphine; Clinical Trials, Phase III as Topic; Coitus; Cross-Over Studies; Dopamine Agonists; Dose-Response Relationship, Drug; Double-Blind Method; Erectile Dysfunction; Humans; Male; Middle Aged; Nausea; Penile Erection; Research Design; Safety; Time Factors; Treatment Outcome | 2000 |
New treatment for erectile dysfunction.
Topics: Apomorphine; Clinical Trials as Topic; Dopamine Agonists; Erectile Dysfunction; Humans; Male; Phosphodiesterase Inhibitors; Piperazines; Purines; Sildenafil Citrate; Sulfones; Vasodilator Agents | 2000 |
Erectile dysfunction.
Topics: Adrenergic alpha-Antagonists; Alprostadil; Androgens; Apomorphine; Dopamine Agonists; Erectile Dysfunction; Humans; Male; Prevalence; Vasodilator Agents | 2001 |
Pharmacology of erectile function and dysfunction.
Topics: Animals; Apomorphine; Dopamine Agonists; Endothelins; Erectile Dysfunction; Humans; Male; Penile Erection; Receptors, Adrenergic; Receptors, Dopamine; Receptors, Endothelin; Selective Serotonin Reuptake Inhibitors; Trazodone; Vasoactive Intestinal Peptide | 2001 |
Oral drug therapy for erectile dysfunction.
Topics: 3',5'-Cyclic-GMP Phosphodiesterases; Administration, Oral; Apomorphine; Cardiovascular System; Contraindications; Coronary Disease; Cyclic Nucleotide Phosphodiesterases, Type 5; Dopamine Agonists; Erectile Dysfunction; Heart; Humans; Male; Phosphodiesterase Inhibitors; Piperazines; Prostatectomy; Purines; Sildenafil Citrate; Spinal Cord Injuries; Sulfones | 2001 |
Apomorphine to Uprima: the development of a practical erectogenic drug: a personal perspective.
Topics: Administration, Oral; Animals; Apomorphine; Canada; Clinical Trials, Phase IV as Topic; Dopamine Agonists; Drug Approval; Erectile Dysfunction; History, 19th Century; History, 20th Century; Humans; Male; Penile Erection; Technology, Pharmaceutical | 2001 |
Characterising the benefit of apomorphine SL (Uprima) as an optimised treatment for representative populations with erectile dysfunction.
Topics: Administration, Sublingual; Apomorphine; Dopamine Agonists; Erectile Dysfunction; Humans; Male | 2001 |
Safety and tolerability of apomorphine SL (Uprima).
Topics: Administration, Sublingual; Apomorphine; Dopamine Agonists; Erectile Dysfunction; Humans; Male; Safety | 2001 |
New oral agents for erectile dysfunction: what is changing in our practice?
Topics: Administration, Oral; Apomorphine; Dopamine Agonists; Erectile Dysfunction; Humans; Male; Phosphodiesterase Inhibitors; Practice Patterns, Physicians'; Urology | 2001 |
Current treatments and emerging therapeutic approaches in male erectile dysfunction.
Topics: Adrenergic alpha-Antagonists; Alprostadil; Apomorphine; Erectile Dysfunction; Humans; Hypogonadism; Imidazoles; Male; Penile Implantation; Physical Therapy Modalities; Piperazines; Psychotherapy; Purines; Sildenafil Citrate; Sulfones; Testosterone; Triazines; Vacuum; Vardenafil Dihydrochloride; Vascular Surgical Procedures; Vasodilator Agents; Yohimbine | 2001 |
The pharmacology and clinical pharmacokinetics of apomorphine SL.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Apomorphine; Chemical and Drug Induced Liver Injury; Dopamine Agonists; Erectile Dysfunction; Humans; Kidney Diseases; Male; Middle Aged | 2001 |
Efficacy of apomorphine SL in erectile dysfunction.
Topics: Adult; Apomorphine; Clinical Trials as Topic; Dopamine Agonists; Erectile Dysfunction; Humans; Male; Quality of Life; Time Factors; Treatment Outcome | 2001 |
Mode of action of a new oral treatment for erectile dysfunction: apomorphine SL.
Topics: Administration, Oral; Apomorphine; Dopamine Agonists; Erectile Dysfunction; Humans; Male | 2001 |
Safety and tolerability of apomorphine SL in patients with erectile dysfunction.
Topics: Adult; Aged; Alcohol Drinking; Antiemetics; Apomorphine; Cardiovascular Agents; Dopamine Agonists; Drug Interactions; Electrocardiography; Erectile Dysfunction; Humans; Male; Middle Aged | 2001 |
The role of apomorphine SL in the treatment of male erectile dysfunction.
Topics: Apomorphine; Dopamine Agonists; Erectile Dysfunction; Humans; Male | 2001 |
Oral treatment of erectile dysfunction with apomorphine SL.
Topics: Administration, Oral; Apomorphine; Dopamine Agonists; Erectile Dysfunction; Heart Diseases; Humans; Male; Penile Erection; Risk Factors | 2001 |
Dopamine and male sexual function.
Topics: Animals; Apomorphine; Dopamine; Dopamine Agonists; Erectile Dysfunction; Humans; Male; Nucleus Accumbens; Paraventricular Hypothalamic Nucleus; Penile Erection; Preoptic Area; Sexual Behavior, Animal; Spinal Cord | 2001 |
Sublingual apomorphine for the treatment of erectile dysfunction.
Topics: Administration, Sublingual; Apomorphine; Clinical Trials as Topic; Dopamine Agonists; Erectile Dysfunction; Humans; Male; Penile Erection; Time Factors | 2002 |
Apomorphine SL (Uprima): preclinical and clinical experiences learned from the first central nervous system-acting ED drug.
Topics: Animals; Apomorphine; Dopamine Agents; Erectile Dysfunction; Humans; Male; Penile Erection | 2002 |
Economic aspects of medical erectile dysfunction therapies.
Topics: Apomorphine; Cost-Benefit Analysis; Dopamine Agonists; Erectile Dysfunction; Humans; Injections; Male; Penis; Phosphodiesterase Inhibitors; Piperazines; Purines; Sildenafil Citrate; Sulfones; Urethra | 2002 |
26 trial(s) available for apomorphine and Impotence
Article | Year |
---|---|
[Efficacy of compound Xuanju Capsule combined with apomorphine hydrochloride on erectile dysfunction].
Topics: Adult; Aged; Apomorphine; Capsules; Drug Therapy, Combination; Drugs, Chinese Herbal; Erectile Dysfunction; Humans; Male; Middle Aged; Phytotherapy; Treatment Outcome; Young Adult | 2012 |
Comparative cross-over study of sildenafil and apomorphine for treating erectile dysfunction.
Topics: Adult; Aged; Apomorphine; Coitus; Cross-Over Studies; Erectile Dysfunction; Humans; Male; Middle Aged; Patient Satisfaction; Penile Erection; Phosphodiesterase Inhibitors; Piperazines; Prospective Studies; Purines; Sildenafil Citrate; Sulfones; Treatment Outcome | 2008 |
An open-label, randomized, flexible-dose, crossover study to assess the comparative efficacy and safety of sildenafil citrate and apomorphine hydrochloride in men with erectile dysfunction.
Topics: Adult; Apomorphine; Cross-Over Studies; Dopamine; Erectile Dysfunction; Humans; Male; Middle Aged; Piperazines; Purines; Research Design; Safety; Sildenafil Citrate; Sulfones; Surveys and Questionnaires; Time Factors; Vasodilator Agents | 2008 |
Inhalation device allows novel administration of apomorphine in men with erectile dysfunction-efficacy and safety findings.
Topics: Administration, Inhalation; Adult; Aged; Apomorphine; Dopamine Agonists; Dose-Response Relationship, Drug; Drug-Related Side Effects and Adverse Reactions; Erectile Dysfunction; Humans; Male; Middle Aged; Penile Erection; Powders; Sexual Behavior; Treatment Outcome | 2010 |
Brain activation patterns during video sexual stimulation following the administration of apomorphine: results of a placebo-controlled study.
Topics: Administration, Sublingual; Aged; Apomorphine; Arousal; Brain; Brain Mapping; Double-Blind Method; Erectile Dysfunction; Erotica; Humans; Image Processing, Computer-Assisted; Magnetic Resonance Imaging; Male; Middle Aged; Penile Erection; Reference Values; Sensitivity and Specificity; Video Recording | 2003 |
Effects of visual sexual stimuli and apomorphine SL on cerebral activity in men with erectile dysfunction.
Topics: Adult; Apomorphine; Arousal; Central Nervous System; Dopamine Agonists; Erectile Dysfunction; Erotica; Humans; Male; Penile Erection; Probability; Reference Values; Regional Blood Flow; Sensitivity and Specificity; Tomography, Emission-Computed | 2003 |
Apomorphine-induced brain modulation during sexual stimulation: a new look at central phenomena related to erectile dysfunction.
Topics: Adult; Apomorphine; Brain; Case-Control Studies; Coitus; Cross-Over Studies; Dopamine Agonists; Double-Blind Method; Erectile Dysfunction; Frontal Lobe; Humans; Limbic System; Magnetic Resonance Imaging; Male; Placebos; Psychophysiologic Disorders | 2003 |
Efficacy and safety of daily intake of apomorphine SL in men affected by erectile dysfunction and mild hyperprolactinemia: a prospective, open-label, pilot study.
Topics: Adult; Apomorphine; Delayed-Action Preparations; Drug Administration Schedule; Erectile Dysfunction; Follicle Stimulating Hormone; Humans; Hyperprolactinemia; Luteinizing Hormone; Male; Middle Aged; Penile Erection; Pilot Projects; Prospective Studies; Safety; Testosterone; Treatment Outcome; Ultrasonography | 2003 |
Clinical experience with apomorphine hydrochloride: the first 107 patients.
Topics: Adult; Aged; Aged, 80 and over; Apomorphine; Erectile Dysfunction; Humans; Male; Middle Aged | 2003 |
A comparative, crossover study of the efficacy and safety of sildenafil and apomorphine in men with evidence of arteriogenic erectile dysfunction.
Topics: Apomorphine; Arteries; Cross-Over Studies; Dopamine Agonists; Erectile Dysfunction; Humans; Male; Middle Aged; Patient Satisfaction; Piperazines; Purines; Sildenafil Citrate; Sulfones; Treatment Outcome; Vascular Diseases; Vasodilator Agents | 2004 |
An open-label, randomized, flexible-dose, crossover study to assess the comparative efficacy and safety of sildenafil citrate and apomorphine hydrochloride in men with erectile dysfunction.
Topics: Adult; Aged; Aged, 80 and over; Apomorphine; Cross-Over Studies; Erectile Dysfunction; Humans; Male; Middle Aged; Phosphodiesterase Inhibitors; Piperazines; Purines; Sildenafil Citrate; Sulfones; Treatment Outcome; Vasodilator Agents | 2004 |
Efficacy of apomorphine and sildenafil in men with nonarteriogenic erectile dysfunction. A comparative crossover study.
Topics: Apomorphine; Cross-Over Studies; Erectile Dysfunction; Humans; Male; Middle Aged; Penile Erection; Phosphodiesterase Inhibitors; Piperazines; Prospective Studies; Purines; Sildenafil Citrate; Sulfones; Treatment Outcome | 2004 |
Prospective, randomized, crossover comparison of sublingual apomorphine (3 mg) with oral sildenafil (50 mg) for male erectile dysfunction.
Topics: Administration, Oral; Administration, Sublingual; Adult; Aged; Apomorphine; Cross-Over Studies; Dopamine Agonists; Erectile Dysfunction; Humans; Male; Middle Aged; Phosphodiesterase Inhibitors; Piperazines; Prospective Studies; Purines; Sildenafil Citrate; Sulfones | 2004 |
Sexual dysfunction in patients under dialytic treatment.
Topics: Adult; Aged; Apomorphine; Erectile Dysfunction; Humans; Male; Middle Aged; Phosphodiesterase Inhibitors; Piperazines; Prospective Studies; Purines; Renal Dialysis; Sildenafil Citrate; Sulfones | 2006 |
Comparative trial of treatment satisfaction, efficacy and tolerability of sildenafil versus apomorphine in erectile dysfunction--an open, randomized cross-over study with flexible dosing.
Topics: Adolescent; Adult; Aged; Apomorphine; Coitus; Cross-Over Studies; Erectile Dysfunction; Humans; Male; Middle Aged; Orgasm; Patient Satisfaction; Penile Erection; Piperazines; Purines; Sexual Partners; Sildenafil Citrate; Sulfones; Surveys and Questionnaires; Treatment Outcome | 2007 |
[Intraurethrally applicated alprostadil for the treatment of organic erectile dysfunction in practice: a multicenter clinical monitoring study (noninterventional investigation)].
Topics: Aged; Aged, 80 and over; Alprostadil; Apomorphine; Body Mass Index; Dopamine Agonists; Double-Blind Method; Drug Therapy, Combination; Erectile Dysfunction; Humans; Injections; Male; Middle Aged; Orgasm; Penile Erection; Phosphodiesterase Inhibitors; Postoperative Complications; Quality of Life; Urethra; Vasodilator Agents | 2007 |
Effect of blood sampling on apomorphine-induced penile tumescence in erectile impotence: a case report.
Topics: Apomorphine; Erectile Dysfunction; Humans; Hyperprolactinemia; Male; Middle Aged; Penile Erection; Testosterone | 1995 |
Recovery of erectile function by the oral administration of apomorphine.
Topics: Administration, Sublingual; Adult; Aged; Apomorphine; Erectile Dysfunction; Humans; Male; Middle Aged; Penile Erection | 1995 |
Efficacy and safety of fixed-dose and dose-optimization regimens of sublingual apomorphine versus placebo in men with erectile dysfunction. The Apomorphine Study Group.
Topics: Administration, Sublingual; Adult; Aged; Apomorphine; Dopamine Agonists; Double-Blind Method; Erectile Dysfunction; Humans; Male; Middle Aged | 2000 |
Double-blind, crossover comparison of 3 mg apomorphine SL with placebo and with 4 mg apomorphine SL in male erectile dysfunction.
Topics: Administration, Sublingual; Adult; Aged; Apomorphine; Coitus; Cross-Over Studies; Dopamine Agonists; Double-Blind Method; Erectile Dysfunction; Humans; Male; Middle Aged | 2001 |
An open-label, uncontrolled dose-optimization study of sublingual apomorphine in erectile dysfunction.
Topics: Administration, Sublingual; Adult; Aged; Apomorphine; Dopamine Agonists; Dose-Response Relationship, Drug; Erectile Dysfunction; Humans; Male; Middle Aged | 2001 |
Cardiovascular safety of sublingual apomorphine in patients on stable doses of oral antihypertensive agents and nitrates.
Topics: Administration, Sublingual; Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Analysis of Variance; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Apomorphine; Calcium Channel Blockers; Cross-Over Studies; Diuretics; Dopamine Agonists; Double-Blind Method; Electrocardiography, Ambulatory; Erectile Dysfunction; Heart Rate; Humans; Hypertension; Male; Middle Aged; Nitrates; Treatment Outcome | 2001 |
A European multicentre study to evaluate the tolerability of apomorphine sublingual administered in a forced dose-escalation regimen in patients with erectile dysfunction.
Topics: Administration, Sublingual; Adolescent; Adult; Aged; Apomorphine; Dopamine Agonists; Dose-Response Relationship, Drug; Double-Blind Method; Erectile Dysfunction; Europe; Humans; Male; Middle Aged; Tablets; Treatment Outcome | 2002 |
Combination therapy for erectile dysfunction: a randomized, double blind, unblinded active-controlled, cross-over study of the pharmacodynamics and safety of combined oral formulations of apomorphine hydrochloride, phentolamine mesylate and papaverine hyd
Topics: Adrenergic alpha-Antagonists; Apomorphine; Cross-Over Studies; Double-Blind Method; Drug Combinations; Erectile Dysfunction; Humans; Male; Papaverine; Phentolamine; Piperazines; Purines; Safety; Severity of Illness Index; Sildenafil Citrate; Sulfones; Treatment Outcome; Vasodilator Agents | 2002 |
Apomorphine: clinical studies on erectile impotence and yawning.
Topics: Adult; Apomorphine; Diabetes Mellitus, Type 2; Erectile Dysfunction; Humans; Lithium; Male; Middle Aged; Penis; Yawning | 1989 |
Apomorphine-induced penile tumescence in impotent patients--preliminary findings.
Topics: Adult; Apomorphine; Bromocriptine; Dose-Response Relationship, Drug; Erectile Dysfunction; Humans; Male; Middle Aged; Penile Erection; Prognosis; Prolactin | 1987 |
56 other study(ies) available for apomorphine and Impotence
Article | Year |
---|---|
Discovery of 2-(4-pyridin-2-ylpiperazin-1-ylmethyl)-1H-benzimidazole (ABT-724), a dopaminergic agent with a novel mode of action for the potential treatment of erectile dysfunction.
Topics: Animals; Benzimidazoles; Cell Line; Erectile Dysfunction; Ferrets; Humans; Male; Penile Erection; Piperazines; Pyridines; Radioligand Assay; Rats; Rats, Wistar; Receptors, Dopamine D2; Receptors, Dopamine D4; Structure-Activity Relationship; Vomiting | 2004 |
1-aryl-3-(4-pyridine-2-ylpiperazin-1-yl)propan-1-one oximes as potent dopamine D4 receptor agonists for the treatment of erectile dysfunction.
Topics: Animals; Benzamides; Binding Sites; Cell Line; Crystallography, X-Ray; Disease Models, Animal; Drug Evaluation, Preclinical; Erectile Dysfunction; Ferrets; Humans; Male; Models, Molecular; Molecular Structure; Oximes; Piperazines; Rats; Rats, Wistar; Receptors, Dopamine D4; Stereoisomerism; Structure-Activity Relationship | 2006 |
Discovery of 3-methyl-N-(1-oxy-3',4',5',6'-tetrahydro-2'H-[2,4'-bipyridine]-1'-ylmethyl)benzamide (ABT-670), an orally bioavailable dopamine D4 agonist for the treatment of erectile dysfunction.
Topics: Action Potentials; Administration, Oral; Animals; Benzamides; Biological Availability; Cell Line; Cyclic N-Oxides; Dogs; Erectile Dysfunction; ERG1 Potassium Channel; Ether-A-Go-Go Potassium Channels; Haplorhini; Humans; In Vitro Techniques; Male; Patch-Clamp Techniques; Purkinje Fibers; Rats; Receptors, Dopamine D4; Structure-Activity Relationship | 2006 |
Dopamine D2 receptors in the nucleus accumbens modulate erectile function in a rat model of nonorganic erectile dysfunction.
Topics: Animals; Apomorphine; Dopamine; Erectile Dysfunction; Humans; Male; Nucleus Accumbens; Rats; Receptors, Dopamine D1; Receptors, Dopamine D2; Sucrose; Tyrosine 3-Monooxygenase | 2022 |
High-Salt Intake Reduces Apomorphine-Induced Penile Erection and Increases Neurally Mediated Contractile Responses of the Cavernosal Smooth Muscle in Rats.
Topics: Animals; Apomorphine; Calcium Signaling; Electric Stimulation; Erectile Dysfunction; Male; Muscle Contraction; Muscle, Smooth; Penile Erection; Penis; Rats, Wistar; rho-Associated Kinases; Sodium Chloride, Dietary | 2019 |
Changes in Male Rat Sexual Behavior and Brain Activity Revealed by Functional Magnetic Resonance Imaging in Response to Chronic Mild Stress.
Topics: Animals; Apomorphine; Brain; Depression; Disease Models, Animal; Erectile Dysfunction; Female; Magnetic Resonance Imaging; Male; Penile Erection; Rats; Rats, Wistar; Sexual Behavior | 2018 |
Dopamine D2 receptors in the basolateral amygdala modulate erectile function in a rat model of nonorganic erectile dysfunction.
Topics: Animals; Apomorphine; Basolateral Nuclear Complex; Disease Models, Animal; Dopamine Agonists; Dopamine D2 Receptor Antagonists; Erectile Dysfunction; Male; Penile Erection; Rats; Rats, Wistar; Receptors, Dopamine D2; Sexual Behavior, Animal; Stress, Psychological | 2019 |
Chromatographic analysis of some drugs employed in erectile dysfunction therapy: qualitative and quantitative studies using calixarene stationary phase.
Topics: Apomorphine; Buffers; Calixarenes; Carbolines; Chromatography, High Pressure Liquid; Erectile Dysfunction; Humans; Hydrogen-Ion Concentration; Limit of Detection; Male; Pharmaceutical Preparations; Piperazines; Purines; Reproducibility of Results; Sildenafil Citrate; Sulfonamides; Tadalafil | 2014 |
[Therapeutic efficacy of Bushengzhuyang Fang (Yangjing Capsule) on phytoestrogen-induced erectile dysfunction: an experimental study].
Topics: Animals; Apomorphine; Drugs, Chinese Herbal; Erectile Dysfunction; Humans; Isoflavones; Luteinizing Hormone; Male; Penile Erection; Penis; Phytoestrogens; Phytotherapy; Piperazines; Purines; Rats; Rats, Sprague-Dawley; Sildenafil Citrate; Sulfonamides; Testosterone; Vasodilator Agents | 2014 |
[Expressions of HO-2 and CO in the corpus cavernosum of castrated rats].
Topics: Animals; Apomorphine; Carbon Monoxide; Dopamine Agonists; Erectile Dysfunction; Humans; Male; Molecular Chaperones; Orchiectomy; Penile Erection; Penis; Random Allocation; Rats; Rats, Sprague-Dawley | 2015 |
[Expression of nNOS and ultrastructural changes in the penile tissue of rats with prolactinoma-induced erectile dysfunction].
Topics: Animals; Apomorphine; Carcinogens; Diethylstilbestrol; Erectile Dysfunction; Humans; Male; Myocytes, Smooth Muscle; Nitric Oxide Synthase Type I; Organ Size; Penile Erection; Penis; Pituitary Neoplasms; Prolactin; Prolactinoma; Rats; Rats, Wistar; Testosterone | 2015 |
Role of endothelin receptors and relationship with nitric oxide synthase in impaired erectile response in diabetic rats.
Topics: Animals; Apomorphine; Bosentan; Diabetes Mellitus, Experimental; Dopamine Agonists; Endothelin Receptor Antagonists; Endothelin-1; Erectile Dysfunction; Humans; Male; Nitric Oxide; Nitric Oxide Synthase Type II; Nitric Oxide Synthase Type III; Penile Erection; Penis; Rats; Rats, Wistar; Receptor, Endothelin A; Receptor, Endothelin B; RNA, Messenger; Sulfonamides; Tumor Necrosis Factor-alpha | 2017 |
[Erectile dysfunctions].
Topics: Adrenergic alpha-Antagonists; Apomorphine; Diagnosis, Differential; Dopamine Agonists; Erectile Dysfunction; Humans; Impotence, Vasculogenic; Male; Penile Implantation; Phosphodiesterase Inhibitors; Risk Factors; Testosterone; Vascular Surgical Procedures; Yohimbine | 2009 |
Erectile function restoration after repair of excised cavernous nerves by autologous vein graft in rats.
Topics: Animals; Apomorphine; Disease Models, Animal; Erectile Dysfunction; Male; Penile Erection; Penis; Rats; Rats, Sprague-Dawley; Transplantation, Autologous; Veins | 2010 |
Morphological and functional evidence for the contribution of the pudendal artery in aging-induced erectile dysfunction.
Topics: Acetylcholine; Aging; Animals; Apomorphine; Arteries; Dose-Response Relationship, Drug; Erectile Dysfunction; Male; Penile Erection; Penis; Phenylephrine; Rats; Rats, Sprague-Dawley | 2010 |
Evaluation and treatment of erectile dysfunction in the aging male: a mini-review.
Topics: Aged; Aged, 80 and over; Aging; Apomorphine; Erectile Dysfunction; Female; Humans; Male; Middle Aged; Phosphodiesterase 5 Inhibitors; Plant Preparations; Prostheses and Implants; Vacuum | 2012 |
[Erectile dysfunction].
Topics: Adrenergic beta-Antagonists; Alprostadil; Apomorphine; Dopamine Agonists; Erectile Dysfunction; Genetic Therapy; Humans; Impotence, Vasculogenic; Male; Penile Erection; Phosphodiesterase Inhibitors; Vasodilator Agents; Yohimbine | 2002 |
Systemic apomorphine alters HPA axis responses to interleukin-1 beta administration but not sound stress.
Topics: Adrenocorticotropic Hormone; Analysis of Variance; Animals; Apomorphine; Dopamine Agonists; Erectile Dysfunction; Hypothalamo-Hypophyseal System; Immunohistochemistry; Interleukin-1; Male; Neural Pathways; Noise; Oncogene Proteins v-fos; Pituitary-Adrenal System; Rats; Rats, Wistar; Stress, Physiological; Stress, Psychological | 2003 |
Evaluating dose regimens of apomorphine, an open-label study.
Topics: Apomorphine; Dopamine Agonists; Erectile Dysfunction; Humans; Male; Medical Records; Middle Aged; Patient Satisfaction; Thailand | 2003 |
Coming attractions! New medications on the horizon for erectile dysfunction.
Topics: Alprostadil; Apomorphine; Carbolines; Drug Approval; Erectile Dysfunction; Genetic Therapy; Global Health; Humans; Male; Phosphodiesterase Inhibitors; Tadalafil; United States; United States Food and Drug Administration | 2003 |
[Drug therapy of erectile dysfunction--the current status].
Topics: Administration, Oral; Administration, Topical; Adrenergic alpha-Antagonists; Alprostadil; Apomorphine; Dopamine Agonists; Erectile Dysfunction; Humans; Male; Penis; Phosphodiesterase Inhibitors; Piperazines; Purines; Sildenafil Citrate; Sulfones; Testosterone; Vasodilator Agents; Yohimbine | 2003 |
Apomorphine sublingual as primary or secondary treatment for erectile dysfunction in patients with spinal cord injury.
Topics: Administration, Sublingual; Adult; Apomorphine; Dopamine Agonists; Electrophysiology; Erectile Dysfunction; Humans; Male; Middle Aged; Prospective Studies; Spinal Cord Injuries; Treatment Outcome; Urodynamics | 2004 |
Nymphaea cults in ancient Egypt and the New World: a lesson in empirical pharmacology.
Topics: Apomorphine; Egypt, Ancient; Erectile Dysfunction; Flowers; History, Ancient; Humans; Male; Medicine, Traditional; Mexico; Nymphaea; Phytotherapy | 2004 |
A prospective evaluation of efficacy and compliance with a multistep treatment approach for erectile dysfunction in patients after non-nerve sparing radical prostatectomy.
Topics: Administration, Sublingual; Aged; Algorithms; Apomorphine; Erectile Dysfunction; Follow-Up Studies; Humans; Male; Patient Compliance; Penile Prosthesis; Piperazines; Postoperative Complications; Prospective Studies; Prostaglandins E; Prostatectomy; Prostatic Neoplasms; Purines; Sildenafil Citrate; Sulfones; Treatment Outcome; Vacuum; Vasodilator Agents | 2005 |
Pharmacotherapy for erectile dysfunction.
Topics: alpha-MSH; Apomorphine; Dopamine Agonists; Drug Therapy, Combination; Erectile Dysfunction; Humans; Isoquinolines; Male; Naltrexone; Naphthyridines; Neuroprotective Agents; Peptides, Cyclic; Phosphodiesterase Inhibitors; Selective Serotonin Reuptake Inhibitors; Sexual Behavior; Trazodone | 2004 |
[Determination of apomorphine, sildenafil and alprostadil in medicines for erectile dysfunction by high performance liquid chromatography-mass spectrometry].
Topics: Alprostadil; Apomorphine; Chromatography, High Pressure Liquid; Dopamine Agonists; Drugs, Chinese Herbal; Erectile Dysfunction; Humans; Male; Mass Spectrometry; Phosphodiesterase Inhibitors; Piperazines; Purines; Sildenafil Citrate; Sulfones | 2005 |
Examination of the safety and use of apomorphine prescribed in general practice in England as a treatment for erectile dysfunction.
Topics: Adult; Adverse Drug Reaction Reporting Systems; Aged; Aged, 80 and over; Apomorphine; Cohort Studies; Dopamine Agonists; England; Erectile Dysfunction; Family Practice; Humans; Male; Middle Aged; Treatment Outcome | 2006 |
Effects of chronic renal failure on the expression of connexin 43 in the rat's corpus cavernosum.
Topics: Animals; Apomorphine; Blotting, Western; Connexin 43; Disease Models, Animal; Erectile Dysfunction; Gene Expression; Kidney Failure, Chronic; Male; Penile Erection; Penis; Rats; Rats, Sprague-Dawley | 2008 |
Commentary on apomorphine versus sildenafil for erectile dysfunction.
Topics: 3',5'-Cyclic-GMP Phosphodiesterases; Apomorphine; Dopamine Agonists; Erectile Dysfunction; Humans; Male; Penile Erection; Phosphodiesterase Inhibitors; Piperazines; Purines; Sildenafil Citrate; Sulfones; Treatment Outcome | 2008 |
[Establishment of a rat model of diabetic erectile dysfunction].
Topics: Animals; Apomorphine; Diabetes Mellitus, Experimental; Disease Models, Animal; Erectile Dysfunction; Male; Random Allocation; Rats; Rats, Sprague-Dawley; Streptozocin | 2008 |
Apomorphine-induced penile erections in Parkinson's disease.
Topics: Adult; Aged; Antiparkinson Agents; Apomorphine; Erectile Dysfunction; Humans; Injections, Subcutaneous; Male; Middle Aged; Parkinson Disease; Penile Erection | 1998 |
Apomorphine (TAP holdings). 6a beta-aporphine-10,11-diol hydrochloride hemihydrate, apomorphine hydrochloride, spontane, Uprima.
Topics: Apomorphine; Clinical Trials, Phase III as Topic; Dopamine Agonists; Erectile Dysfunction; Humans; Male; Placebos; Receptors, Dopamine D2 | 1999 |
FDA committee recommends approval for viagra rival.
Topics: Apomorphine; Dopamine Agonists; Drug Approval; Erectile Dysfunction; Humans; Male; United States; United States Food and Drug Administration | 2000 |
Delayed testosterone replacement restores nitric oxide synthase-containing nerve fibres and the erectile response in rat penis.
Topics: Animals; Apomorphine; Castration; Erectile Dysfunction; Hormone Replacement Therapy; Male; Nerve Fibers; Nitric Oxide Synthase; Penile Erection; Penis; Rats; Rats, Sprague-Dawley; Testosterone | 2000 |
Looking beyond Viagra. The 30 million American men with impotence problems may soon have two oral treatments to choose from. How do they compare?
Topics: Apomorphine; Erectile Dysfunction; Humans; Male; Piperazines; Purines; Sildenafil Citrate; Sulfones | 2000 |
[Erectile dysfunction: an update on new therapeutic options].
Topics: 3',5'-Cyclic-GMP Phosphodiesterases; Aged; Apomorphine; Clinical Trials as Topic; Cyclic Nucleotide Phosphodiesterases, Type 5; Dopamine Agonists; Erectile Dysfunction; Humans; Male; Nitric Oxide Donors; Phosphodiesterase Inhibitors; Phosphoric Diester Hydrolases; Piperazines; Purines; Sildenafil Citrate; Sulfones | 2000 |
Current concepts in erectile dysfunction.
Topics: Administration, Oral; Adult; Aged; Algorithms; Apomorphine; Comorbidity; Dopamine Agonists; Erectile Dysfunction; Humans; Male; Medical History Taking; Middle Aged; Penile Implantation; Phosphodiesterase Inhibitors; Physical Examination; Piperazines; Prostaglandins; Purines; Sildenafil Citrate; Sulfones; United States | 2000 |
Clinical perspective on erectile dysfunction therapies.
Topics: Adult; Aged; Apomorphine; Counseling; Dopamine Agonists; Erectile Dysfunction; Humans; Male; Middle Aged; Phosphodiesterase Inhibitors; Piperazines; Primary Health Care; Purines; Sexual Partners; Sildenafil Citrate; Sulfones | 2000 |
Key issues from the clinical trials of apomorphine SL.
Topics: Adolescent; Adult; Aged; Apomorphine; Clinical Trials as Topic; Erectile Dysfunction; Humans; Male; Middle Aged | 2001 |
[Soon there will be potency pills for every need. What is the value of the new viagra competitors? (interview by Dr. Brigitte Moreano)].
Topics: Apomorphine; Erectile Dysfunction; Humans; Male; Phosphodiesterase Inhibitors; Piperazines; Purines; Sildenafil Citrate; Sulfones; Treatment Outcome | 2001 |
Apomorphine SL (Uprima): a new treatment for the management of erectile dysfunction.
Topics: Administration, Sublingual; Apomorphine; Dopamine Agonists; Erectile Dysfunction; Humans; Male | 2001 |
Competition for Viagra.
Topics: Apomorphine; Dopamine Agonists; Erectile Dysfunction; Humans; Male | 2001 |
[Erectile dysfunction. Help also for cardiac patients].
Topics: Apomorphine; Contraindications; Coronary Disease; Drug Interactions; Erectile Dysfunction; Humans; Male; Molsidomine; Nitrates; Piperazines; Purines; Sildenafil Citrate; Sulfones | 2001 |
Erectile dysfunction occurs following substantia nigra lesions in the rat.
Topics: Animals; Apomorphine; Behavior, Animal; Brain Diseases; Corpus Striatum; Dopamine; Dopamine Agonists; Electric Stimulation; Erectile Dysfunction; Male; Nervous System; Oxidopamine; Penile Erection; Penis; Pressure; Rats; Rats, Sprague-Dawley; Substantia Nigra | 2001 |
Sequential administration enhances the effect of apomorphine SL in men with erectile dysfunction.
Topics: Administration, Sublingual; Apomorphine; Dose-Response Relationship, Drug; Erectile Dysfunction; Humans; Male; Randomized Controlled Trials as Topic; Retreatment | 2002 |
[Hypertension and impotence. Which potency drug is the most appropriate here?].
Topics: Antihypertensive Agents; Apomorphine; Clinical Trials as Topic; Dopamine Agonists; Drug Interactions; Erectile Dysfunction; Humans; Hypertension; Male; Phosphodiesterase Inhibitors; Piperazines; Purines; Sildenafil Citrate; Sulfones | 2002 |
Apomorphine as an alternative to sildenafil in Parkinson's disease.
Topics: Antiparkinson Agents; Apomorphine; Erectile Dysfunction; Humans; Injections, Subcutaneous; Male; Multiple System Atrophy; Parkinson Disease; Phosphodiesterase Inhibitors; Piperazines; Purines; Sildenafil Citrate; Sulfones | 2002 |
Development of a rat model of sexual performance anxiety: effect of behavioural and pharmacological hyperadrenergic stimulation on APO-induced erections.
Topics: Animals; Anxiety Disorders; Apomorphine; Blood Pressure; Disease Models, Animal; Erectile Dysfunction; Heart Rate; Hemodynamics; Male; Methoxamine; Penile Erection; Rats; Rats, Wistar; Sexual Behavior, Animal; Stress, Psychological; Sympathetic Nervous System | 2002 |
Sublingual apomorphine: new preparation. In erectile disorders: a narrow therapeutic margin.
Topics: Administration, Oral; Apomorphine; Clinical Trials as Topic; Dopamine Agonists; Erectile Dysfunction; Europe; Humans; Male; Penile Erection; Phosphodiesterase Inhibitors; Piperazines; Randomized Controlled Trials as Topic; Treatment Outcome; United States | 2002 |
[Experiences with apomorphine SL in studies: tolerated therapy--even in problem patients].
Topics: Apomorphine; Clinical Trials as Topic; Drug Interactions; Erectile Dysfunction; Humans; Male; Patient Compliance | 2002 |
[Erectile dysfunction. Breaking through the silence].
Topics: Apomorphine; Erectile Dysfunction; Humans; Male; Patient Education as Topic; Physician-Patient Relations; Treatment Outcome | 2002 |
[Progress in therapy of erectile dysfunction. New orally administered drugs].
Topics: Administration, Oral; Apomorphine; Clinical Trials as Topic; Erectile Dysfunction; Humans; Male; Phentolamine; Piperazines; Purines; Sildenafil Citrate; Sulfones; Trazodone; Treatment Outcome; Vasodilator Agents; Yohimbine | 2002 |
Activation with (+/-)N-n-propyl-nor-apomorphine (NPA) of the male rat copulatory behavior.
Topics: Animals; Apomorphine; Copulation; Ejaculation; Erectile Dysfunction; Humans; Male; Rats; Stimulation, Chemical | 1979 |
Effect of bromocriptine in patients with apomorphine-responsive erectile impotence: an open study.
Topics: Adult; Apomorphine; Bromocriptine; Erectile Dysfunction; Humans; Male; Middle Aged | 1991 |
Effect of apomorphine on penile tumescence in men with psychogenic impotence.
Topics: Apomorphine; Double-Blind Method; Erectile Dysfunction; Humans; Male; Penile Erection | 1991 |
[What can be expected of intracavernous injections?].
Topics: Adult; Aged; Apomorphine; Erectile Dysfunction; Humans; Injections; Injections, Subcutaneous; Male; Middle Aged; Moxisylyte; Papaverine; Penis; Vasodilator Agents | 1988 |